Exp Mol Med.
2007 Jun;39(3):361-366.
Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast ancer risk in Korean women
- Affiliations
-
- 1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. kyyoo@plaza.snu.ac.kr
- 2Research Institute for National Cancer Control and Evaluation, National Cancer Center, Goyang 410-769, Korea.
- 3Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY, USA.
- 4Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.
- 5Department of Surgery, Seoul National University College of Medicine, Seoul 110-799, Korea.
- 6Department of Surgery, Ulsan University College of Medicine, Seoul 138-736, Korea.
- 7National Cancer Center, Goyang 410-769, Korea.
Abstract
- Cytochrome P450 1A1 (CYP1A1) is involved in the 2-hydroxylation of estrogen, the hormone that plays a critical role in the etiology of breast carcinoma. We evaluated the associations between two CYP1A1 polymorphisms [MspI (rs4646903); Ile462Val (rs1048943)] and breast cancer in a multicenter case-control study of 513 breast cancer cases and 447 controls in Korea. Women carrying the T allele of the CYP1A1 MspI polymorphism were found to have a 1.72-fold (95% CI 1.11-2.68) greater risk of developing breast cancer. No association was found between any CYP1A1 Ile462Val polymorphism and breast cancer. Haplotype analysis of the two loci showed that the CA haplotype was associated with the lowest risk of breast cancer, and CA/CA diplotypes were associated with a lower risk of breast cancer [OR = 0.28 (0.13-0.61)] than others/others diplotypes. Moreover, this reduced risk was more pronounced among women with a lower body mass index (BMI) [OR = 0.18 (0.06-0.58)] or with a shorter lifetime exposure to estrogen [OR = 0.23 (0.07-0.81)]. The results obtained suggest that the CYP1A1 MspI polymorphisms could affect susceptibility to breast cancer.